51 articles
Genetic modeling shows RNA interference and antibody-based PCSK9 inhibitors deliver equivalent cardiovascular benefits when matched for apoB reduction.
New clinical trials show GLP-1 medications like Ozempic can reverse fatty liver disease in up to 62% of patients within 72 weeks.
Discover which three blood biomarker tests offer the highest value for catching silent health risks before they become deadly.
Researcher Mike Lustgarten analyzes his latest blood panel for biological age, cardiovascular risk, and diet correlations.
The new ACC/AHA guideline introduces childhood screening, Lp(a) testing, and LDL-C treatment targets that reshape primary prevention care.
An 80-week Amgen-sponsored Phase 3 trial evaluated evolocumab's safety and efficacy in pediatric patients aged 10–17 with inherited high LDL cholesterol.
Phase 4 trial tests whether alirocumab can better control non-HDL cholesterol in high-risk type 2 diabetics failing statin therapy.
A Phase 3 trial pits monthly lerodalcibep against evolocumab in homozygous familial hypercholesterolemia patients over 24 weeks.
A Saudi Arabia survey reveals alarming gaps in ApoB testing knowledge among physicians and pharmacists, despite clear guideline recommendations.
A Phase 2 trial pits NNC0385-0434 tablets against evolocumab injections in high-risk cardiovascular patients — could a daily pill replace the shot?
A genomic study of 3,358 biopsy-proven MASLD patients finds APOB pathogenic variants linked to significantly higher steatosis and liver injury scores.
Phase 3 trial pits lerodalcibep against inclisiran to determine which PCSK9 inhibitor best cuts LDL in cardiovascular high-risk patients.
